# Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Rela

Source: https://onco.cc/trials/nct07411599/  
OnCo record `nct07411599` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cyclophosphamide, fludarabine and cetuximab in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") is a phase 1/2, interventional study registered as NCT07411599 by M.D. Anderson Cancer Center, with a registry enrolment figure of 28 participants, started 2026-04-20 and due to reach its primary completion in 2028-11-15. Interventions recorded: Cyclophosphamide; Fludarabine; Cetuximab; NK Cells. Conditions listed: Colorectal Cancer; Peritoneal Metastases; Carcinomatosis. Primary outcome: Safety and adverse events (AEs. Colorectal eligibility wording from the registry: "o History of hysterectomy or bilateral salpingo-oophorectomy". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07411599
- Phase: 1/2
- Setting: Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT07411599: https://clinicaltrials.gov/study/NCT07411599

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07411599.json